Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
6 Months : From Jun 2019 to Dec 2019
By Allison Prang
The European Medicines Agency's Committee for Medicinal Products for Human Use is recommending that approval for an atopic dermatitis treatment from Regeneron Pharmaceuticals Inc. and Sanofi be extended, the companies said Friday.
The committee is recommending that the European Union approval be extended to also include people with moderate-to-severe cases of this type of dermatitis who are systemic therapy candidates and between ages 12 and 17, the companies said.
They said they expect the European Commission's final decision on the treatment's application should come in the coming months.
Write to Allison Prang at email@example.com
(END) Dow Jones Newswires
June 28, 2019 07:48 ET (11:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.